Menu Back to 17th-DIA-Japan-Annual-Meeting-2020

Overview

Virtual Event

Click Here to View the Program in Japanese

Click Here to View the Program in English

Taking the theme “Beyond Innovation”, the Japan Annual Meeting 2020 will bring together academia, regulators, industry professionals, and patients from across the world to exchange information and discuss the latest trends in the discovery, development, and lifecycle management of pharmaceuticals, medical devices, and related products.

This is the largest event in the DIA Japan annual calendar and features more than 60 sessions on topics ranging from Risk Management, Patient Engagement and Pharmacovigilance to the 30th anniversary of ICH, the future of Healthcare, and the COVID-19 pandemic. Our hugely popular PMDA Town Hall DIAmond session also makes a return to the program.

This year’s Meeting will be held entirely online through a fully integrated platform offering live and on-demand content, live Q&A sessions with speakers, group and 1-2-1 networking opportunities and much more! Breaking walls and boundaries, the virtual platform will enable you to join the event from wherever you may be and to connect with fellow professionals from across the world.

We look forward to seeing you there!

Event Concept

In recent years, while the fourth industrial revolution progresses, various new initiatives on innovation, which lead to novel values or substantial changes in healthcare product research & development, have begun by creation and usage of brand new ideas and technologies such as artificial intelligence, big data and utilization of medical and genome information.

There are two categories of innovation; disruptive innovation, which could bring drastic changes in the way we think and do things, and sustaining innovation, which could bring an improvement of products and services by using technology refinement in the existing platform. Important thing is that; we need to actively learn the cutting-edge technologies supporting various innovations, continuously think how our day-to-day work is going to change in the future, and create skills and mindset which could cope with various new changes. Meanwhile, we would like to encourage key stakeholders in healthcare to step back and think about if the values and changes brought by such innovations would really contribute to health and welfare of patients.

As the theme for the 17th DIA Japan Annual Meeting 2020, we chose the phrase “Beyond Innovation”. With DIA’s mission to provide a neutral platform for discussion, we would like to convene various stakeholder in Industry, government, academia as well as patients, to learn new technologies and initiatives, and discuss what we should eventually aiming for, leading to further facilitate the progress of healthcare innovation.

Program Committee

  • Yuji  Kumagai, MD, PhD
    Yuji Kumagai, MD, PhD Professor, Clinical Research Center
    Kitasato University Hospital, Japan
  • Keiichi  Inaizumi, MSc
    Keiichi Inaizumi, MSc Japan Clinical Project Manager, Clinical Operations and Compliance 1
    Pfizer R&D Japan, Japan
  • Taro  Amagasaki, PhD
    Taro Amagasaki, PhD Head, Analytics Japan
    Novartis Pharma K.K., Japan
  • Nobuyuki  Hanamura, PhD, MBA
    Nobuyuki Hanamura, PhD, MBA Senior Director, Clinical Development Strategy & Solutions
    Japan
  • Toshiko  Ishibashi, PhD, RN
    Toshiko Ishibashi, PhD, RN Clinical Operation I, Clinical Operation Management
    Ono Pharmaceutical Co., Ltd., Japan
  • Kazuhiko  Ishida, MSc, RPh
    Kazuhiko Ishida, MSc, RPh Director, Risk Management, Pharmacovigilance
    Astellas Pharma Inc., Japan
  • Yayoi  Kitawaki, MS
    Yayoi Kitawaki, MS Senior Japan Program Head, Oncology Development Unit, Japan Development
    Novartis Pharma K.K., Japan
  • Yoshiko  Komuro, PhD
    Yoshiko Komuro, PhD Inspector Director, Office of Non-clinical and Clinical Compliance
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Takashi  Moriya, PhD, MBA
    Takashi Moriya, PhD, MBA Director
    Janssen Pharmaceutical K.K., Japan
  • Sumimasa  Nagai, MD, PhD
    Sumimasa Nagai, MD, PhD Senior Assistant Professor, Translational Research Center
    The University of Tokyo Hospital, Japan
  • Shinichi  Nishiuma, MD
    Shinichi Nishiuma, MD Executive Director, Head of Medical Affairs, Japan
    Celgene K.K., Japan
  • Mika  Ogasawara
    Mika Ogasawara Quality Lead, Biometrics and Data Management
    Pfizer R&D Japan, Japan
  • Goshi  Ozawa, MS
    Goshi Ozawa, MS Exective officer, RWD dept.
    Real World Data Co., Japan
  • Keiko  Tsumori
    Keiko Tsumori Associate Director, Medical Writing, Regulatory Affairs Area, Japan Development
    MSD K.K., Japan
  • Junichi  Nishino, MSc, RPh
    Junichi Nishino, MSc, RPh Director, Medical Regulatory Affairs Department
    Otsuka Pharmaceutical Co., Ltd., Japan
  • Hironobu  Saito, PhD
    Hironobu Saito, PhD Corporate Officer /Head of Medical Affairs Div.
    Daiichi Sankyo Co., Ltd., Japan
  • Junko  Sato, PhD
    Junko Sato, PhD Director, Office of International Programs
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Takashi  Sato, MSc, PMP
    Takashi Sato, MSc, PMP Manager, Project Management Group, R&D Planning Department
    Kyowa Kirin Co., Ltd., Japan
  • Atsushi  Tsukamoto, PhD, MSc
    Atsushi Tsukamoto, PhD, MSc
    Daiichi Sankyo Company, Limited, Japan
Load More

Contact us